RECRUITINGINTERVENTIONAL
Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers
Development of a Prospective and Monocentric Cinical and Biological Database in Epithelial Ovarian Cancer, Fallopian Tube Cancer and Primitive Peritoneal Cancer
About This Trial
A Clinical and Biological Database will provide to the scientific community a collection of blood and tissues with clinical datas to improve knowledge about cancer and help to develope new cancer treatments. This database is specific to epithetial ovarian cancer, Fallopian tube cancer and Primitive peritoneal cancer.
Who May Be Eligible (Plain English)
Who May Qualify:
- 18 or older
- Patient at the diagnosis of an epithelial ovarian cancer, or a fallopian tube caner or a primitive peritoneal cancer
- Patient eligible for, at least, one surgery and a chemotherapy
- Patient having given his informed, written and express consent
Who Should NOT Join This Trial:
- Patient not affiliated to a social protection scheme
- Pregnant and / or nursing women
- Subject under tutelage, curatorship or safeguard of justice
- Patient whose regular follow-up is impossible for psychological, familial, social or geographical reasons
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* 18 or older
* Patient at the diagnosis of an epithelial ovarian cancer, or a fallopian tube caner or a primitive peritoneal cancer
* Patient eligible for, at least, one surgery and a chemotherapy
* Patient having given his informed, written and express consent
Exclusion Criteria:
* Patient not affiliated to a social protection scheme
* Pregnant and / or nursing women
* Subject under tutelage, curatorship or safeguard of justice
* Patient whose regular follow-up is impossible for psychological, familial, social or geographical reasons
Treatments Being Tested
OTHER
Biological collection
* Blood samples collected at different times : Before treatment (T1) , after chemotherapy (T2), after interval surgery (T3) and after cancer reccurence (T4) * Tissue samples (tumor tissue and healthy tissue) collected during the surgery
Locations (1)
ICM - Institut régional du Cancer Montpellier
Montpellier, France